Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
#4095 CAPTEM and PRRT to improve overall response for pancreatic NETs (pNETs) – The CORONET trial
Introduction: Patients with advanced pNETs have limited treatment options. The NETTER-2 and OCLURANDOM trials have established peptide receptor radionuclide therapy (PRRT) as a standard treatment in pNETs; CAPTEM chemotherapy is an active regimen in NENs. The CONTROL NETs trial has shown promising response rate and progression-free survival with PRRT+CAPTEM, warranting further investigation.
Conference:
Presenting Author:
Authors: Chan D, Doherty M, Singh S, Michael M, Kong G,
Keywords: PRRT, CAPTEM, Randomized Trial, Phase III,
#3755 Large cell neuroendocrine carcinoma of the breast
Introduction: Primary neuroendocrine breast carcinomas are rare and little-known tumors. They account for only 2 % to 5 % of breast cancers. Diagnosis is based on neuroendocrine architecture associated with the expression of neuroendocrine markers.
Conference:
Presenting Author:
Authors: Samia K, Siham C, Fatima H,
Keywords: large cell neuroendocrine carcinoma, neuroendocrine marker, chromogranin, synaptophysin, mastectomy,
Introduction: Neuroendocrine neoplasms (NEN) represent a diverse group of malignancies. Anatomic origin, histology and biological behaviour vary extensively. The treatment armamentarium includes surgery (first choice when possible), systemic therapy and localised treatment modalities. The role of radiotherapy is not yet established, but studies indicate that local tumor control (LTC) can be achieved by high-dose radiotherapy. Stereotactic ablative radiotherapy (SBRT) is high doses of radiation delivered to a small target, with potential of achieving local tumor control.
Conference:
Presenting Author:
Authors: Nygaard Dowler A, Aggerholm Pedersen N, Knap Marquard M, Dam G, Tabaksblat E,
Keywords: neuroendocrine, stereotactic radiotherapy, sbrt, local control,
Introduction: PRRT has shown favourable results in NETs. Long-term safety and efficacy data for 177Lu-Octreotate PRRT, particularly in combination with chemotherapy, is lacking.
Conference:
Presenting Author: Ransom D
Authors: Ransom D, Kennedy K, Turner J, Macdonald W, Boardman G,
Keywords: PRRT, long term, chemotherapy, leukaemia, myelodysplasia, renal,
Introduction: The treatment landscape for neuroendocrine tumors includes alkylating-agent chemotherapy and peptide receptor radiotherapy (PRRT) with 177Lu-Dotatate. The risk of MDS/AML associated with 177Lu-Dotatate is approximately 2-3%. Several small prior studies have suggested substantially higher rates of MDS/AML (approximately 10%) in patients who have also received alkylating agent chemotherapy with streptozocin or temozolomide, either combined with PRRT or sequentially.
Conference:
Presenting Author:
Authors: Al-Toubah T, Pelle E, Strosberg J,